Meeder Asset Management Inc Galectin Therapeutics Inc Transaction History

Meeder Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.03 - $1.66 $1,872 - $3,017	-1,818 Reduced 32.26%	3,817 $4,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $421 - $798	-322 Reduced 5.41%	5,635 $9,000
Q2 2022 Aug 08, 2022	SELL	$1.19 - $1.74 $2,424 - $3,544	-2,037 Reduced 25.48%	5,957 $7,000
Q1 2022 May 10, 2022	BUY	$1.61 - $2.31 $12,870 - $18,466	7,994 New	7,994 $13,000
Q4 2021 Feb 11, 2022	SELL	$2.07 - $3.8 $16,110 - $29,575	-7,783 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$2.59 - $4.15 $7,422 - $11,893	2,866 Added 58.29%	7,783 $30,000
Q2 2021 Aug 09, 2021	BUY	$2.07 - $5.1 $10,178 - $25,076	4,917 New	4,917 $16,000
Q2 2020 Aug 11, 2020	SELL	$1.66 - $3.15 $308 - $585	-186 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.51 - $3.0 $280 - $558	186 New	186 $0
Q4 2019 Feb 13, 2020	SELL	$2.79 - $4.32 $53 - $82	-19 Closed	0 $0
Q3 2019 Oct 17, 2019	BUY	$3.0 - $4.05 $57 - $76	19 New	19 $0

9.35M

982K

2.7K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $161M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.